MP28-02 COMPARATIVE ANALYSIS OF OUTCOMES OF PAPILLARY TYPE 1 AND TYPE 2 AND CLEAR CELL RENAL CELL CARCINOMA: A MULTI-INSTITUTIONAL STUDY (2018)

You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging I1 Apr 2018MP28-02 COMPARATIVE ANALYSIS OF OUTCOMES OF PAPILLARY TYPE 1 AND TYPE 2 AND CLEAR CELL RENAL CELL CARCINOMA: A MULTI-INSTITUTIONAL STUDY Ahmet Bindayi, Shreyas Joshi, Alessandro Larcher, Madhumitha Reddy, Stephen Ryan, Umberto Capitanio, Zachary Hamilton, Kendrick Yim, Sabrina Noyes, Sumi Dey, Francesco Montorsi, Robert Uzzo, and Ithaar Derweesh Ahmet BindayiAhmet Bindayi More articles by this author , Shreyas JoshiShreyas Joshi More articles by this author , Alessandro LarcherAlessandro Larcher More articles by this author , Madhumitha ReddyMadhumitha Reddy More articles by this author , Stephen RyanStephen Ryan More articles by this author , Umberto CapitanioUmberto Capitanio More articles by this author , Zachary HamiltonZachary Hamilton More articles by this author , Kendrick YimKendrick Yim More articles by this author , Sabrina NoyesSabrina Noyes More articles by this author , Sumi DeySumi Dey More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , Robert UzzoRobert Uzzo More articles by this author , and Ithaar DerweeshIthaar Derweesh More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.902AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Compared to Clear Cell Renal Cell Carcinoma (ccRCC), papillary RCC (pRCC) has been thought of as lower risk pathology associated with higher cancer specific survival (CSS). Impact of histophatological subtypes of pRCC on outcomes is controversial. METHODS The cohort was divided into analytical subgroups based on histology (ccRCC vs. pRCC type I vs. pRCC type II). The primary end-point was overall (OS) and with secondary endpoint was Cancer specific survival (CSS). Kaplan-Meier survival (KMS) and multivariate regression model were used to estimate 5- and 10- year OS and CSS rates and the predictors associated with CSS. RESULTS 6377 Patients were as analyzed (pRCC type I n = 469, pRCC type II n = 473 and ccRCC n = 5435). MVA revealed that increasing tumor size (OR 1.222, p < 0.001), pRCC type I vs. ccRCC (OR 0.482, p = 0.002), higher Fuhrman grade (OR 2.409, p = 0.009), lymphovascular invasion (OR 2.735, p = 0.018) and necrosis in pathology (OR 1.976, p = 0.035) were significant risk factors for cancer specific mortality (Table). KMS showed that OS rates in patients with pRCC type I, II and ccRCC were 82, 74 and 76% at 5 years and 72.5, 48, 60.3% at 10 years, respectively (p = 0.001). CSS rates in patients with pRCC type I, II and ccRCC were 98, 90.6 and 86.6% at 5 years and 97.5, 78.3 and 79.5% at 10 years, respectively (p < 0.001). CONCLUSIONS pRCC type II represents a higher risk than histopathological subtype pRCC Type I, with oncological outcomes comparable to ccRCC. Our findings suggest that surveillance and adjuvant therapeutic investigational strategy should be further refined to address increased risk of pRCC type 2. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e356-e357 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Ahmet Bindayi More articles by this author Shreyas Joshi More articles by this author Alessandro Larcher More articles by this author Madhumitha Reddy More articles by this author Stephen Ryan More articles by this author Umberto Capitanio More articles by this author Zachary Hamilton More articles by this author Kendrick Yim More articles by this author Sabrina Noyes More articles by this author Sumi Dey More articles by this author Francesco Montorsi More articles by this author Robert Uzzo More articles by this author Ithaar Derweesh More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...